Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Mixed results seen with depsipeptide in radioiodine-refractory thyroid cancer

June 9, 2009

MKC-1 shows limited activity in platinum-resistant ovarian cancer

June 9, 2009

ASCO snapshots: Agents investigated in leukemia, myelodysplasia

June 9, 2009

(R)-Gossypol is safe and well tolerated in glioblastoma and lymphoma patients in phase II trials

June 9, 2009

Additive antitumor activity seen with oncolytic measles virus and bevacizumab in glioma model

June 9, 2009

FDA grants orphan drug designation to Delcath's melphalan for neuroendocrine tumors

June 8, 2009

Phase II data on olaparib in breast, ovarian cancer reported at ASCO

June 8, 2009

ACT signs exclusive license for anticancer therapeutic from University of Louisville

June 8, 2009

Hsp27 inhibitor OGX-427 well tolerated, affects tumor markers in phase I study

June 8, 2009

German regulator clears Silence Therapeutics' CTA for phase I study of ATU-027 in cancer

June 5, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 30, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Taiwan biotech looks outward in next phase of growth
BioWorld
Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to...